Research Directions in Genetically-Mediated Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
Research Directions in Genetically-Mediated Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis March 3-4, 2015 National Institutes of Health, Bethesda, MD Recognizing recent breakthroughs in identifying genetic causes of SJS/TEN and the relative dearth of U.S. funded research in this area, the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) sponsored a workshop entitled, “Research Directions in Genetically-Mediated Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN).” The meeting was organized as a series of talks and discussions covering the state of the science, international experiences, challenges in case-findings and surveillance, and special topics. There were break-out sessions focused on gaps and opportunities in basic research, clinical implementation and pharmacosurveillance.
March 3 - 4, 2015
Building 31 Conference Center (6th floor of 31C)
NIH Main Campus
Bethesda, Md.
On March 3-4, 2015, the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) sponsored a workshop - Research Directions in Genetically-Mediated Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis - at Building 31 on the NIH main campus.
The objectives of the workshop are to:
- Review the current state of knowledge of the surveillance, pathogenesis and treatment of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN).
- Examine the role of genomics and pharmacogenomics in the etiology, treatment and eradication of preventable causes of drug-induced SJS/TEN.
- Identify the gaps, unmet needs and priorities for future research to eliminate genetically mediated SJS/TEN globally.
